A study reports high sensitivity and specificity of a cell-free DNA blood-based assay compared to colonoscopy

In the NORPACT-1 study, adjuvant FOLFORINOX shows no additional benefit compared to upfront surgery in patients with resectable pancreatic ductal adenocarcinoma

The two Pan-Asian Guideline Adaptations of parental ESMO Clinical Practice Guidelines reflect the younger age of disease occurrence and lack of some treatment data in Asia  

Data from the IMbrave050 study show benefits of atezolizumab plus bevacizumab in terms of disease recurrence, but long-term data are needed  

Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment 

Negative results from the ASCOT trial should not discourage researchers from investigating the drug’s potential in some molecularly distinct subgroups

Despite positive results from trials, the use of different assays with variable sensitivities and specificities impact their interpretation and clinical validation

In the NICHE-3 study, all patients achieved a pathological response  

Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens 

Results from the JCOG1611-GENERATE trial fuel the debate around the preferred option in this setting